Who owns CONTEXT THERAPEUTICS INC COM?
- Ticker: CNTX
- CUSIP Number: 21077p108
Tip: Access positions for across all investors
Analyze quarterly positions in Context Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Context Therapeutics stock
Who bought or sold CONTEXT THERAPEUTICS INC COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| MPM Oncology Impact Management | 15M | $14M | 0% | Sep 2025 |
|
| Avidity Partners Management | 9.0M | $8.7M | 20% | Sep 2025 |
|
| Deep Track Capital | 7.4M | $7.2M | 0% | Sep 2025 |
|
| Nextech Invest | 7.4M | $7.2M | 0% | Sep 2025 |
|
| Blue Owl Capital Holdings | 7.4M | $7.2M | 0% | Sep 2025 |
|
| Dr. Jeffrey R. Jay, M.D. | 4.7M | $4.5M | 0% | Sep 2025 |
|
| Franklin Resources | 4.0M | $3.9M | 0% | Sep 2025 |
|
| Vanguard Group | 3.5M | $3.4M | 4% | Sep 2025 |
|
| Blackstone Group | 2.4M | $2.4M | 0% | Sep 2025 |
|
| Alyeska Investment Group | 1.7M | $1.6M | 0% | Sep 2025 |
|
| Nantahala Capital Management | 1.7M | $1.6M | -14% | Sep 2025 |
|
| Sio Capital Management | 1.3M | $1.3M | 0% | Sep 2025 |
|
| BlackRock | 849k | $823k | 0% | Sep 2025 |
|
| Geode Capital Management | 609k | $590k | -5% | Sep 2025 |
|
| Affinity Asset Advisors | 403k | $390k | -22% | Sep 2025 |
|
| ADAR1 Capital Management | 351k | $340k | 0% | Sep 2025 |
|
| Renaissance Technologies | 320k | $310k | -12% | Sep 2025 |
|
| State Street Corporation | 153k | $148k | 0% | Sep 2025 |
|
| Walleye Trading Advisors | 133k | $129k | 0% | Sep 2025 |
|
| HighTower Advisors | 126k | $122k | 0% | Sep 2025 |
|
| Pathstone Holdings | 110k | $107k | 100% | Sep 2025 |
|
| Mill Creek Capital Advisors | 105k | $101k | 0% | Sep 2025 |
|
| Citadel Advisors | 103k | $100k | 100% | Sep 2025 |
|
| Velan Capital Investment Management | 100k | $97k | 0% | Sep 2025 |
|
| Clear Harbor Asset Management | 93k | $90k | 61% | Sep 2025 |
|
| Qube Research & Technologies | 82k | $80k | -23% | Sep 2025 |
|
| Northern Trust | 66k | $64k | -42% | Sep 2025 |
|
| Marshall Wace | 36k | $35k | 100% | Sep 2025 |
|
| Advisor Group Holdings | 26k | $25k | 143% | Sep 2025 |
|
| Susquehanna International | 22k | $21k | 100% | Sep 2025 |
|
| HPM Partners | 20k | $19k | 0% | Sep 2025 |
|
| Caxton | 18k | $18k | 0% | Sep 2025 |
|
| Congress Wealth Management LLC / DE / | 15k | $9.8k | 0% | Jun 2025 |
|
| XTX Topco | 11k | $10k | 100% | Sep 2025 |
|
| UBS Group | 7.4k | $7.2k | 1895% | Sep 2025 |
|
| Morgan Stanley | 3.5k | $2.3k | 100% | Jun 2025 |
|
| Barclays | 167.00 | $162.006700 | 100% | Sep 2025 |
|
| SBI Securities | 117.00 | $112.998600 | 4% | Sep 2025 |
|
Who sold out of Context Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Woodline Partners | Jun 2025 | 680k | $446k |
| Luminus Management | Jun 2025 | 328k | $215k |
| Gts Securities | Jun 2025 | 44k | $29k |
| Millennium Management | Jun 2025 | 17k | $11k |
| Tower Research Capital | Jun 2025 | 7.4k | $4.9k |
| Newbridge Financial Services Group | Jun 2025 | 2.0k | $1.3k |